The Role of Macrophages in Cancer: From Basic Research to Clinical Applications

Abstract

Macrophages are innate immune cells that extensively infiltrate and play a key role in the tumor microenvironment (TME). Tumor cell–secreted factors recruit monocytes into the TME, where they differentiate into tumor-associated macrophages (TAMs), which can polarize into distinct phenotypes: M1 and M2. M1 TAMs promote antitumor immunity through cytokine secretion and antigen presentation, whereas M2 TAMs support tumor progression by facilitating angiogenesis, invasion, and immune escape. Despite these dual roles, the specific mechanisms governing macrophage plasticity and polarization remain insufficiently understood. This review comprehensively summarizes the origin, polarization, and functional diversity of macrophages in the TME, with emphasis on pathways that regulate TAM-mediated immune responses. Furthermore, this article examines current TAM-targeted therapeutic strategies, including recruitment inhibition, phenotypic reprogramming, and the development of chimeric antigen receptor macrophages (CAR-Ms), as well as macrophage-based drug delivery and exosome therapy. By integrating recent advances in cell engineering and immunometabolism, this review highlights the translational potential of TAM-targeted therapies and their value in reshaping the immunosuppressive TME to enhance cancer immunotherapy.

Keywords

CAR-M / cell therapy / macrophages / tumor-associated macrophages / tumor microenvironment

References

[1] T. A. Wynn, A. Chawla, and J. W. Pollard, “Macrophage Biology in Development, Homeostasis and Disease,” Nature 496 (2013): 445–455.

[2] Y. Lavin and M. Merad, “Macrophages: Gatekeepers of Tissue Integrity,” Cancer Immunology Research 1 (2013): 201–209.

[3] Y. Lavin, D. Winter, R. Blecher-Gonen, et al., “Tissue-Resident Macrophage Enhancer Landscapes Are Shaped by the Local Microenvironment,” Cell 159 (2014): 1312–1326.

[4] M. D. Park, A. Silvin, F. Ginhoux, and M. Merad, “Macrophages in Health and Disease,” Cell 185 (2022): 4259–4279.

[5] R. Y. Ma, A. Black, and B. Z. Qian, “Macrophage Diversity in Cancer Revisited in the Era of Single-Cell Omics,” Trends in Immunology 43 (2022): 546–563.

[6] M. Locati, G. Curtale, and A. Mantovani, “Diversity, Mechanisms, and Significance of Macrophage Plasticity,” Annual Review of Pathology 15 (2020): 123–147.

[7] Z. Liu, Y. Gu, S. Chakarov, et al., “Fate Mapping via Ms4a3-Expression History Traces Monocyte-Derived Cells,” Cell 178 (2019): 1509–1525. e1519.

[8] Z. Bian, Y. Gong, T. Huang, et al., “Deciphering Human Macrophage Development at Single-Cell Resolution,” Nature 582 (2020): 571–576.

[9] J. Sheng, C. Ruedl, and K. Karjalainen, “Most Tissue-Resident Macrophages Except Microglia Are Derived From Fetal Hematopoietic Stem Cells,” Immunity 43 (2015): 382–393.

[10] G. Eraslan, E. Drokhlyansky, S. Anand, et al., “Single-Nucleus Cross-Tissue Molecular Reference Maps Toward Understanding Disease Gene Function,” Science 376 (2022): eabl4290.

[11] E. Gomez Perdiguero, K. Klapproth, C. Schulz, et al., “Tissue-Resident Macrophages Originate From Yolk-sac-Derived Erythro-Myeloid Progenitors,” Nature 518 (2015): 547–551.

[12] G. Hoeffel, J. Chen, Y. Lavin, et al., “C-Myb(+) Erythro-Myeloid Progenitor-Derived Fetal Monocytes Give Rise to Adult Tissue-Resident Macrophages,” Immunity 42 (2015): 665–678.

[13] A. Plein, A. Fantin, L. Denti, J. W. Pollard, and C. Ruhrberg, “Erythro-Myeloid Progenitors Contribute Endothelial Cells to Blood Vessels,” Nature 562 (2018): 223–228.

[14] F. Ginhoux and M. Guilliams, “Tissue-Resident Macrophage Ontogeny and Homeostasis,” Immunity 44 (2016): 439–449.

[15] T. Heidt, G. Courties, P. Dutta, et al., “Differential Contribution of Monocytes to Heart Macrophages in Steady-State and After Myocardial Infarction,” Circulation Research 115 (2014): 284–295.

[16] S. Epelman, K. J. Lavine, and G. J. Randolph, “Origin and Functions of Tissue Macrophages,” Immunity 41 (2014): 21–35.

[17] T. Fuchs, K. Puellmann, A. Emmert, et al., “The Macrophage-TCRαβ Is a Cholesterol-Responsive Combinatorial Immune Receptor and Implicated in Atherosclerosis,” Biochemical and Biophysical Research Communications 456 (2015): 59–65.

[18] C. Schneider, S. P. Nobs, M. Kurrer, H. Rehrauer, C. Thiele, and M. Kopf, “Induction of the Nuclear Receptor PPAR-γ by the Cytokine GM-CSF Is Critical for the Differentiation of Fetal Monocytes Into Alveolar Macrophages,” Nature Immunology 15 (2014): 1026–1037.

[19] B. B. Ural, S. T. Yeung, P. Damani-Yokota, et al., “Identification of a Nerve-Associated, Lung-Resident Interstitial Macrophage Subset With Distinct Localization and Immunoregulatory Properties,” Science Immunology 5 (2020): eaax8756.

[20] C. F. Nathan, H. W. Murray, M. E. Wiebe, and B. Y. Rubin, “Identification of Interferon-Gamma as the Lymphokine That Activates Human Macrophage Oxidative Metabolism and Antimicrobial Activity,” Journal of Experimental Medicine 158 (1983): 670–689.

[21] T. R. Mosmann and R. L. Coffman, “TH1 and TH2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties,” Annual Review of Immunology 7 (1989): 145–173.

[22] M. Stein, S. Keshav, N. Harris, and S. Gordon, “Interleukin 4 Potently Enhances Murine Macrophage Mannose Receptor Activity: A Marker of Alternative Immunologic Macrophage Activation,” Journal of Experimental Medicine 176 (1992): 287–292.

[23] A. Salminen, “Activation of Immunosuppressive Network in the Aging Process,” Ageing Research Reviews 57 (2020): 100998.

[24] P. Riquelme, J. Haarer, A. Kammler, et al., “TIGIT(+) iTregs Elicited by human Regulatory Macrophages Control T Cell Immunity,” Nature Communications 9 (2018): 2858.

[25] A. Sharma, P. Sharma, L. Ganga, et al., “Infective Larvae of Brugia malayi Induce Polarization of Host Macrophages That Helps in Immune Evasion,” Frontiers in Immunology 9 (2018): 194.

[26] P. Riquelme, S. Tomiuk, A. Kammler, et al., “IFN-γ-Induced iNOS Expression in Mouse Regulatory Macrophages Prolongs Allograft Survival in Fully Immunocompetent Recipients,” Molecular Therapy 21 (2013): 409–422.

[27] J. A. Hutchinson, P. Riquelme, B. Sawitzki, et al., “Cutting Edge: Immunological Consequences and Trafficking of Human Regulatory Macrophages Administered to Renal Transplant Recipients,” Journal of Immunology 187 (2011): 2072–2078.

[28] S. Su, J. Zhao, Y. Xing, et al., “Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages,” Cell 175 (2018): 442–457. e423.

[29] P. J. Koelink, F. M. Bloemendaal, B. Li, et al., “Anti-TNF Therapy in IBD Exerts Its Therapeutic Effect Through Macrophage IL-10 Signalling,” Gut 69 (2020): 1053–1063.

[30] Y. Degboé, B. Rauwel, M. Baron, et al., “Polarization of Rheumatoid Macrophages by TNF Targeting through an IL-10/STAT3 Mechanism,” Frontiers in Immunology 10 (2019): 3.

[31] J. A. Hutchinson, N. Ahrens, and E. K. Geissler, “MITAP-Compliant Characterization of Human Regulatory Macrophages,” Transplant International 30 (2017): 765–775.

[32] J. A. Hutchinson, F. Gövert, P. Riquelme, et al., “Administration of Donor-Derived Transplant Acceptance-Inducing Cells to the Recipients of Renal Transplants From Deceased Donors Is Technically Feasible,” Clinical Transplantation 23 (2009): 140–145.

[33] J. A. Hutchinson, B. G. Brem-Exner, P. Riquelme, et al., “A Cell-Based Approach to the Minimization of Immunosuppression in Renal Transplantation,” Transplant International 21 (2008): 742–754.

[34] A. Hartnell, J. Steel, H. Turley, M. Jones, D. G. Jackson, and P. R. Crocker, “Characterization of Human Sialoadhesin, a Sialic Acid Binding Receptor Expressed by Resident and Inflammatory Macrophage Populations,” Blood 97 (2001): 288–296.

[35] A. Chow, D. Lucas, A. Hidalgo, et al., “Bone Marrow CD169+ Macrophages Promote the Retention of Hematopoietic Stem and Progenitor Cells in the Mesenchymal Stem Cell Niche,” Journal of Experimental Medicine 208 (2011): 261–271.

[36] H. Kim, J. H. Park, H. C. Kim, C. W. Kim, I. Kang, and H. K. Lee, “Blood Monocyte-Derived CD169(+) Macrophages Contribute to Antitumor Immunity Against Glioblastoma,” Nature Communications 13 (2022): 6211.

[37] S. T. Yeung, L. J. Ovando, A. J. Russo, V. A. Rathinam, and K. M. Khanna, “CD169+ Macrophage Intrinsic IL-10 Production Regulates Immune Homeostasis During Sepsis,” Cell Reports 42 (2023): 112171.

[38] L. Batoon, S. M. Millard, M. E. Wullschleger, et al., “CD169(+) macrophages Are Critical for Osteoblast Maintenance and Promote Intramembranous and Endochondral Ossification During Bone Repair,” Biomaterials 196 (2019): 51–66.

[39] J. Liao, D. Zeng, J. Li, et al., “Type I IFNs Repolarized a CD169(+) Macrophage Population With Anti-Tumor Potentials in Hepatocellular Carcinoma,” Molecular Therapy 30 (2022): 632–643.

[40] A. W. Beham, K. Puellmann, R. Laird, et al., “A TNF-Regulated Recombinatorial Macrophage Immune Receptor Implicated in Granuloma Formation in Tuberculosis,” PLOS Pathogens 7 (2011): e1002375.

[41] T. Fuchs, K. Puellmann, M. Hahn, et al., “A Second Combinatorial Immune Receptor in Monocytes/Macrophages Is Based on the TCRγδ,” Immunobiology 218 (2013): 960–968.

[42] T. Fuchs, M. Hahn, V. Riabov, et al., “A Combinatorial Αβ T Cell Receptor Expressed by Macrophages in the Tumor Microenvironment,” Immunobiology 222 (2017): 39–44.

[43] Y. Jiang, S. Zhang, L. Tang, et al., “Single-Cell RNA Sequencing Reveals TCR(+) Macrophages in HPV-Related Head and Neck Squamous Cell Carcinoma,” Frontiers in Immunology 13 (2022): 1030222.

[44] Y. Zhu, J. M. Herndon, D. K. Sojka, et al., “Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate From Embryonic Hematopoiesis and Promote Tumor Progression,” Immunity 47 (2017): 323–338. e326.

[45] S. Wang, Y. Yang, P. Ma, et al., “CAR-Macrophage: An Extensive Immune Enhancer to Fight Cancer,” EBioMedicine 76 (2022): 103873.

[46] S. K. Biswas, P. Allavena, and A. Mantovani, “Tumor-Associated Macrophages: Functional Diversity, Clinical Significance, and Open Questions,” Seminars in Immunopathology 35 (2013): 585–600.

[47] S. M. Pyonteck, L. Akkari, A. J. Schuhmacher, et al., “CSF-1R Inhibition Alters Macrophage Polarization and Blocks Glioma Progression,” Nature Medicine 19 (2013): 1264–1272.

[48] R. Noy and J. W. Pollard, “Tumor-Associated Macrophages: From Mechanisms to Therapy,” Immunity 41 (2014): 49–61.

[49] E. Bonavita, M. R. Galdiero, S. Jaillon, and A. Mantovani, “Phagocytes as Corrupted Policemen in Cancer-Related Inflammation,” Advances in Cancer Research 128 (2015): 141–171.

[50] P. Loyher, P. Hamon, M. Laviron, et al., “Macrophages of Distinct Origins Contribute to Tumor Development in the Lung,” Journal of Experimental Medicine 215 (2018): 2536–2553.

[51] F. Ginhoux, J. L. Schultze, P. J. Murray, J. Ochando, and S. K. Biswas, “New Insights Into the Multidimensional Concept of Macrophage Ontogeny, Activation and Function,” Nature Immunology 17 (2016): 34–40.

[52] P. J. Murray, “Macrophage Polarization,” Annual Review of Physiology 79 (2017): 541–566.

[53] O. R. Colegio, N. Chu, A. L. Szabo, et al., “Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid,” Nature 513 (2014): 559–563.

[54] K. C. El Kasmi and K. R. Stenmark, “Contribution of Metabolic Reprogramming to Macrophage Plasticity and Function,” Seminars in Immunology 27 (2015): 267–275.

[55] A. Billiau and P. Matthys, “Interferon-Gamma: A Historical Perspective,” Cytokine & Growth Factor Reviews 20 (2009): 97–113.

[56] M. Orecchioni, Y. Ghosheh, A. B. Pramod, and K. Ley, “Macrophage Polarization: Different Gene Signatures in M1(LPS+) Vs. Classically and M2(LPS-) Vs. Alternatively Activated Macrophages,” Frontiers in Immunology 10 (2019): 1084.

[57] A. J. Fleetwood, T. Lawrence, J. A. Hamilton, and A. D. Cook, “Granulocyte-Macrophage Colony-Stimulating Factor (CSF) and Macrophage CSF-Dependent Macrophage Phenotypes Display Differences in Cytokine Profiles and Transcription Factor Activities: Implications for CSF Blockade in Inflammation,” Journal of Immunology 178 (2007): 5245–5252.

[58] Y. Jiao, T. Zhang, C. Zhang, et al., “Exosomal miR-30d-5p of Neutrophils Induces M1 Macrophage Polarization and Primes Macrophage Pyroptosis in Sepsis-Related Acute Lung Injury,” Critical Care (London, England) 25 (2021): 356.

[59] N. Wang, H. Liang, and K. Zen, “Molecular Mechanisms That Influence the Macrophage m1-m2 Polarization Balance,” Frontiers in Immunology 5 (2014): 614.

[60] X. Shan, P. Hu, L. Ni, et al., “Serine Metabolism Orchestrates Macrophage Polarization by Regulating the IGF1-p38 Axis,” Cellular Molecular Immunology 19 (2022): 1263–1278.

[61] C. Kerneur, C. E. Cano, and D. Olive, “Major Pathways Involved in Macrophage Polarization in Cancer,” Frontiers in Immunology 13 (2022): 1026954.

[62] D. Saliba, A. Heger, H. Eames, et al., “IRF5:RelA Interaction Targets Inflammatory Genes in Macrophages,” Cell Reports 8 (2014): 1308–1317.

[63] M. Tellechea, M. Buxadé, S. Tejedor, J. Aramburu, and C. López-Rodríguez, “NFAT5-Regulated Macrophage Polarization Supports the Proinflammatory Function of Macrophages and T Lymphocytes,” Journal of Immunology 200 (2018): 305–315.

[64] H. Huerga Encabo, L. Traveset, J. Argilaguet, et al., “The Transcription Factor NFAT5 Limits Infection-Induced Type I Interferon Responses,” Journal of Experimental Medicine 217 (2020): jem.20190449.

[65] E. L. Mills, B. Kelly, A. Logan, et al., “Succinate Dehydrogenase Supports Metabolic Repurposing of Mitochondria to Drive Inflammatory Macrophages,” Cell 167 (2016): 457–470. e413.

[66] G. M. Tannahill, A. M. Curtis, J. Adamik, et al., “Succinate Is an Inflammatory Signal That Induces IL-1β Through HIF-1α,” Nature 496 (2013): 238–242.

[67] S. B. Weisser, K. W. McLarren, N. Voglmaier, et al., “Alternative Activation of Macrophages by IL-4 Requires SHIP Degradation,” European Journal of Immunology 41 (2011): 1742–1753.

[68] J. Baardman, S. G. S. Verberk, S. van der Velden, et al., “Macrophage ATP Citrate Lyase Deficiency Stabilizes Atherosclerotic Plaques,” Nature Communications 11 (2020): 6296.

[69] X. Qiao, Z. Hu, F. Xiong, et al., “Lipid Metabolism Reprogramming in Tumor-Associated Macrophages and Implications for Therapy,” Lipids in Health and Disease 22 (2023): 45.

[70] R. M. O'Connell, D. Kahn, W. S. Gibson, et al., “MicroRNA-155 Promotes Autoimmune Inflammation by Enhancing Inflammatory T Cell Development,” Immunity 33 (2010): 607–619.

[71] V. R. Ramirez-Carrozzi, D. Braas, D. M. Bhatt, et al., “A Unifying Model for the Selective Regulation of Inducible Transcription by CpG Islands and Nucleosome Remodeling,” Cell 138 (2009): 114–128.

[72] C. Li, X. Xu, S. Wei, P. Jiang, L. Xue, and J. Wang, “Tumor-Associated Macrophages: Potential Therapeutic Strategies and Future Prospects in Cancer,” Journal for ImmunoTherapy of Cancer 9 (2021): e001341.

[73] G. Liu and H. Yang, “Modulation of Macrophage Activation and Programming in Immunity,” Journal of Cellular Physiology 228 (2013): 502–512.

[74] F. De Santa, L. Vitiello, A. Torcinaro, and E. Ferraro, “The Role of Metabolic Remodeling in Macrophage Polarization and Its Effect on Skeletal Muscle Regeneration,” Antioxid Redox Signaling 30 (2019): 1553–1598.

[75] L. Sun, T. Kees, A. S. Almeida, et al., “Activating a Collaborative Innate-Adaptive Immune Response to Control Metastasis,” Cancer Cell 39 (2021): 1361–1374. e1369.

[76] J. M. Jaynes, R. Sable, M. Ronzetti, et al., “Mannose Receptor (CD206) Activation in Tumor-Associated Macrophages Enhances Adaptive and Innate Antitumor Immune Responses,” Science Translational Medicine 12 (2020): eaax6337.

[77] Y. Hattori, D. Kato, F. Murayama, et al., “CD206(+) Macrophages Transventricularly Infiltrate the Early Embryonic Cerebral Wall to Differentiate Into Microglia,” Cell Reports 42 (2023): 112092.

[78] M. N. Hasan, O. Capuk, S. M. Patel, and D. Sun, “The Role of Metabolic Plasticity of Tumor-Associated Macrophages in Shaping the Tumor Microenvironment Immunity,” Cancers (Basel) 14 (2022): 3331.

[79] I. Larionova, E. Kazakova, M. Patysheva, and J. Kzhyshkowska, “Transcriptional, Epigenetic and Metabolic Programming of Tumor-Associated Macrophages,” Cancers (Basel) 12 (2020): 1411.

[80] C. Porta, A. Sica, and E. Riboldi, “Tumor-Associated Myeloid Cells: New Understandings on Their Metabolic Regulation and Their Influence in Cancer Immunotherapy,” FEBS Journal 285 (2018): 717–733.

[81] A. E. de Groot and K. J. Pienta, “Epigenetic Control of Macrophage Polarization: Implications for Targeting Tumor-Associated Macrophages,” Oncotarget 9 (2018): 20908–20927.

[82] Y. Niu, J. Chen, and Y. Qiao, “Epigenetic Modifications in Tumor-Associated Macrophages: A New Perspective for an Old Foe,” Frontiers in Immunology 13 (2022): 836223.

[83] S. M. P. Vadevoo, G. R. Gunassekaran, J. D. Yoo, et al., “Epigenetic Therapy Reprograms M2-Type Tumor-Associated Macrophages Into an M1-Like Phenotype by Upregulating miR-7083-5p,” Frontiers in Immunology 13 (2022): 976196.

[84] S. P. Rebelo, C. Pinto, T. R. Martins, et al., “D-3-Culture: A Tool to Unveil Macrophage Plasticity in the Tumour Microenvironment,” Biomaterials 163 (2018): 185–197.

[85] S. Qin, Z. Wang, C. Huang, P. Huang, and D. Li, “Serine Protease PRSS23 Drives Gastric Cancer by Enhancing Tumor Associated Macrophage Infiltration via FGF2,” Frontiers in Immunology 13 (2022): 955841.

[86] Y. Lu, G. Han, Y. Zhang, et al., “M2 Macrophage-Secreted Exosomes Promote Metastasis and Increase Vascular Permeability in Hepatocellular Carcinoma,” Cell Communication and Signaling 21 (2023): 299.

[87] A. Etzerodt, M. Moulin, T. K. Doktor, et al., “Tissue-Resident Macrophages in Omentum Promote Metastatic Spread of Ovarian Cancer,” Journal of Experimental Medicine 217 (2020): e20191869.

[88] L. Yang, Y. Dong, Y. Li, et al., “IL-10 Derived From M2 Macrophage Promotes Cancer Stemness via JAK1/STAT1/NF-κB/Notch1 Pathway in Non-Small Cell Lung Cancer,” International Journal of Cancer 145 (2019): 1099–1110.

[89] F. Cui, Z. Xu, J. Hu, and Y. Lv, “Spindle Pole Body Component 25 and Platelet-Derived Growth Factor Mediate Crosstalk Between Tumor-Associated Macrophages and Prostate Cancer Cells,” Frontiers in Immunology 13 (2022): 907636.

[90] T. Hagemann, S. C. Robinson, M. Schulz, L. Trümper, F. R. Balkwill, and C. Binder, “Enhanced Invasiveness of Breast Cancer Cell Lines Upon Co-Cultivation With Macrophages Is Due to TNF-Alpha Dependent Up-Regulation of Matrix Metalloproteases,” Carcinogenesis 25 (2004): 1543–1549.

[91] Y. Li, L. Jiang, Y. Chen, et al., “Specific Lineage Transition of Tumor-Associated Macrophages Elicits Immune Evasion of Ascitic Tumor Cells in Gastric Cancer With Peritoneal Metastasis,” Gastric Cancer 27 (2024): 519–538.

[92] C. Chen, L. Zhang, and Z. Ruan, “GATA3 Encapsulated by Tumor-Associated Macrophage-Derived Extracellular Vesicles Promotes Immune Escape and Chemotherapy Resistance of Ovarian Cancer Cells by Upregulating the CD24/Siglec-10 Axis,” Molecular Pharmaceutics 20 (2023): 971–986.

[93] R. Yang, Z. Cai, Y. Zhang, W. H. Yutzy, K. F. Roby, and R. B. Roden, “CD80 in Immune Suppression by Mouse Ovarian Carcinoma-Associated Gr-1+CD11b+ Myeloid Cells,” Cancer Research 66 (2006): 6807–6815.

[94] B. Huang, P. Pan, Q. Li, et al., “Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host,” Cancer Research 66 (2006): 1123–1131.

[95] P. Pan, G. Ma, K. J. Weber, et al., “Immune Stimulatory Receptor CD40 Is Required for T-Cell Suppression and T Regulatory Cell Activation Mediated by Myeloid-Derived Suppressor Cells in Cancer,” Cancer Research 70 (2010): 99–108.

[96] D. Wang, L. Yang, D. Yue, et al., “Macrophage-Derived CCL22 Promotes an Immunosuppressive Tumor Microenvironment via IL-8 in Malignant Pleural Effusion,” Cancer Letters 452 (2019): 244–253.

[97] J. Duraiswamy, G. J. Freeman, and G. Coukos, “Therapeutic PD-1 Pathway Blockade Augments With Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer,” Cancer Research 73 (2013): 6900–6912.

[98] M. Modak, A. Mattes, D. Reiss, et al., “CD206+ Tumor-Associated Macrophages Cross-Present Tumor Antigen and Drive Antitumor Immunity,” JCI Insight 7 (2022): e155022.

[99] C. Zhu, K. Yan, L. Chen, et al., “Targeting OXCT1-Mediated Ketone Metabolism Reprograms Macrophages to Promote Antitumor Immunity via CD8(+) T Cells in Hepatocellular Carcinoma,” Journal of Hepatology 81 (2024): 690–703.

[100] R. E. Menjivar, Z. C. Nwosu, W. Du, et al., “Arginase 1 Is a Key Driver of Immune Suppression in Pancreatic Cancer,” Elife 12 (2023): e80721.

[101] Q. Shi, Q. Shen, Y. Liu, et al., “Increased Glucose Metabolism in TAMs Fuels O-GlcNAcylation of Lysosomal Cathepsin B to Promote Cancer Metastasis and Chemoresistance,” Cancer Cell 40 (2022): 1207–1222. e1210.

[102] L. Chen, L. Huang, Y. Gu, W. Cang, P. Sun, and Y. Xiang, “Lactate-Lactylation Hands Between Metabolic Reprogramming and Immunosuppression,” International Journal of Molecular Sciences 23 (2022): 11943.

[103] D. Zhang, Z. Tang, H. Huang, et al., “Metabolic Regulation of Gene Expression by Histone Lactylation,” Nature 574 (2019): 575–580.

[104] Y. Yang, N. Luo, Z. Gong, W. Zhou, Y. Ku, and Y. Chen, “Lactate and Lysine Lactylation of Histone Regulate Transcription in Cancer,” Heliyon 10 (2024): e38426.

[105] A. De Leo, A. Ugolini, X. Yu, et al., “Glucose-Driven Histone Lactylation Promotes the Immunosuppressive Activity of Monocyte-Derived Macrophages in Glioblastoma,” Immunity 57 (2024): 1105–1123. e1108.

[106] E. Dai, W. Wang, Y. Li, D. Ye, and Y. Li, “Lactate and Lactylation: Behind the Development of Tumors,” Cancer Letters 591 (2024): 216896.

[107] C. Bao, Q. Ma, X. Ying, et al., “Histone Lactylation in Macrophage Biology and Disease: From Plasticity Regulation to Therapeutic Implications,” EBioMedicine 111 (2025): 105502.

[108] Y. Xu, H. Zhang, and D. Nie, “Histone Modifications and Metabolic Reprogramming in Tumor-Associated Macrophages: A Potential Target of Tumor Immunotherapy,” Frontiers in Immunology 16 (2025): 1521550.

[109] Y. Li, Q. Liang, L. Zhou, et al., “An ROS-Responsive Artesunate Prodrug Nanosystem Co-Delivers Dexamethasone for Rheumatoid Arthritis Treatment Through the HIF-1α/NF-κB Cascade Regulation of ROS Scavenging and Macrophage Repolarization,” Acta Biomaterialia 152 (2022): 406–424.

[110] N. Anand, K. H. Peh, and J. M. Kolesar, “Macrophage Repolarization as a Therapeutic Strategy for Osteosarcoma,” International Journal of Molecular Sciences 24 (2023): 2858.

[111] L. Rao, S. Zhao, C. Wen, et al., “Activating Macrophage-Mediated Cancer Immunotherapy by Genetically Edited Nanoparticles,” Advanced Materials 32 (2020): e2004853.

[112] F. Y. McWhorter, T. Wang, P. Nguyen, T. Chung, and W. F. Liu, “Modulation of Macrophage Phenotype by Cell Shape,” PNAS 110 (2013): 17253–17258.

[113] X. Cao, B. Li, J. Chen, et al., “Effect of Cabazitaxel on Macrophages Improves CD47-Targeted Immunotherapy for Triple-Negative Breast Cancer,” Journal for ImmunoTherapy of Cancer 9 (2021): e002022.

[114] Y. Wang, Y. Wang, J. Wang, W. Bai, N. Miao, and J. Wang, “Vinblastine Resets Tumor-Associated Macrophages Toward M1 Phenotype and Promotes Antitumor Immune Response,” Journal for ImmunoTherapy of Cancer 11 (2023): e007253.

[115] J. Van den Bossche, J. Baardman, N. Otto, et al., “Mitochondrial Dysfunction Prevents Repolarization of Inflammatory Macrophages,” Cell Reports 17 (2016): 684–696.

[116] H. Liu, M. Yao, and J. Ren, “Codonopsis pilosula -Derived Glycopeptide dCP1 Promotes the Polarization of Tumor-Associated Macrophage From M2-Like to M1 Phenotype,” Cancer Immunology, Immunotherapy 73 (2024): 128.

[117] C. Zhang, S. Wei, S. Dai, et al., “The NR_109/FUBP1/c-Myc Axis Regulates TAM Polarization and Remodels the Tumor Microenvironment to Promote Cancer Development,” Journal for ImmunoTherapy of Cancer 11 (2023): e006230.

[118] Q. Lv, H. Yang, D. Wang, et al., “Discovery of a Novel CSF-1R Inhibitor With Highly Improved Pharmacokinetic Profiles and Superior Efficacy in Colorectal Cancer Immunotherapy,” Journal of Medicinal Chemistry 67 (2024): 6854–6879.

[119] J. Qiu, T. Ren, Q. Liu, et al., “Dissecting the Distinct Tumor Microenvironments of HRD and HRP Ovarian Cancer: Implications for Targeted Therapies to Overcome PARPi Resistance in HRD Tumors and Refractoriness in HRP Tumors,” Advanced science (Weinheim) 11 (2024): e2309755.

[120] J. G. Valero, A. Matas-Céspedes, F. Arenas, et al., “The Receptor of the Colony-Stimulating Factor-1 (CSF-1R) Is a Novel Prognostic Factor and Therapeutic Target in Follicular Lymphoma,” Leukemia 35 (2021): 2635–2649.

[121] M. Li, M. Li, Y. Yang, et al., “Remodeling Tumor Immune Microenvironment via Targeted Blockade of PI3K-γ and CSF-1/CSF-1R Pathways in Tumor Associated Macrophages for Pancreatic Cancer Therapy,” Journal of Controlled Release 321 (2020): 23–35.

[122] W. Zhang, X. Jiang, Y. Zou, L. Yuan, and X. Wang, “Pexidartinib Synergize PD-1 Antibody Through Inhibiting Treg Infiltration by Reducing TAM-Derived CCL22 in Lung Adenocarcinoma,” Frontiers in Pharmacology 14 (2023): 1092767.

[123] Y. Wei, X. Wang, C. Yan, et al., “Thymosin α-1 Reverses M2 Polarization of Tumor-Associated Macrophages During Efferocytosis,” Cancer Research 82 (2022): 1991–2002.

[124] C. B. Rodell, S. P. Arlauckas, M. F. Cuccarese, et al., “TLR7/8-Agonist-Loaded Nanoparticles Promote the Polarization of Tumour-Associated Macrophages to Enhance Cancer Immunotherapy,” Nature Biomedical Engineering 2 (2018): 578–588.

[125] C. B. Rodell, M. S. Ahmed, C. S. Garris, M. J. Pittet, and R. Weissleder, “Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy,” Theranostics 9 (2019): 8426–8436.

[126] S. Jiang, W. Li, J. Yang, et al., “Cathepsin B-Responsive Programmed Brain Targeted Delivery System for Chemo-Immunotherapy Combination Therapy of Glioblastoma,” ACS Nano 18 (2024): 6445–6462.

[127] B. Wei, J. Pan, R. Yuan, et al., “Polarization of Tumor-Associated Macrophages by Nanoparticle-Loaded Escherichia coli Combined With Immunogenic Cell Death for Cancer Immunotherapy,” Nano Letters 21 (2021): 4231–4240.

[128] J. Li, J. Yang, S. Jiang, et al., “Targeted Reprogramming of Tumor-Associated Macrophages for Overcoming Glioblastoma Resistance to Chemotherapy and Immunotherapy,” Biomaterials 311 (2024): 122708.

[129] L. Sanchez-Moral, T. Paul, C. Martori, et al., “Macrophage CD5L Is a Target for Cancer Immunotherapy,” EBioMedicine 91 (2023): 104555.

[130] H. Cao, Z. Dan, X. He, et al., “Liposomes Coated With Isolated Macrophage Membrane Can Target Lung Metastasis of Breast Cancer,” ACS Nano 10 (2016): 7738–7748.

[131] E. Dolgin, “Cancer-Eating Immune Cells Kitted out With CARs,” Nature Biotechnology 38 (2020): 509–511.

[132] M. Klichinsky, M. Ruella, O. Shestova, et al., “Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy,” Nature Biotechnology 38 (2020): 947–953.

[133] M. A. Morrissey, A. P. Williamson, A. M. Steinbach, et al., “Chimeric Antigen Receptors That Trigger Phagocytosis,” Elife 7 (2018): e36688.

[134] W. Zhang, L. Liu, H. Su, et al., “Chimeric Antigen Receptor Macrophage Therapy for Breast Tumours Mediated by Targeting the Tumour Extracellular Matrix,” British Journal of Cancer 121 (2019): 837–845.

[135] L. Zhang, L. Tian, X. Dai, et al., “Pluripotent Stem Cell-Derived CAR-Macrophage Cells With Antigen-Dependent Anti-Cancer Cell Functions,” Journal of Hematology & Oncology 13 (2020): 153.

[136] A. Lei, H. Yu, S. Lu, et al., “A Second-Generation M1-Polarized CAR Macrophage With Antitumor Efficacy,” Nature Immunology 25 (2024): 102–116.

[137] X. Wang, S. Su, Y. Zhu, et al., “Metabolic Reprogramming via ACOD1 Depletion Enhances Function of Human Induced Pluripotent Stem Cell-Derived CAR-Macrophages in Solid Tumors,” Nature Communications 14 (2023): 5778.

[138] M. Kang, S. H. Lee, M. Kwon, et al., “Nanocomplex-Mediated In Vivo Programming to Chimeric Antigen Receptor-M1 Macrophages for Cancer Therapy,” Advanced Materials 33 (2021): e2103258.

[139] L. Gao, C. Shi, Z. Yang, et al., “Convection-Enhanced Delivery of Nanoencapsulated Gene Locoregionally Yielding ErbB2/Her2-Specific CAR-Macrophages for Brainstem Glioma Immunotherapy,” Journal of Nanobiotechnology 21 (2023): 56.

[140] A. A. Barkal, R. E. Brewer, M. Markovic, et al., “CD24 Signalling Through Macrophage Siglec-10 Is a Target for Cancer Immunotherapy,” Nature 572 (2019): 392–396.

[141] Z. Yang, Y. Liu, K. Zhao, et al., “Dual mRNA Co-Delivery for In Situ Generation of Phagocytosis-Enhanced CAR Macrophages Augments Hepatocellular Carcinoma Immunotherapy,” Journal of Controlled Release 360 (2023): 718–733.

[142] T. Wu, Y. Liu, Y. Cao, and Z. Liu, “Engineering Macrophage Exosome Disguised Biodegradable Nanoplatform for Enhanced Sonodynamic Therapy of Glioblastoma,” Advanced Materials 34 (2022): e2110364.

[143] W. Zhong, Y. Lu, X. Han, et al., “Upregulation of Exosome Secretion From Tumor-Associated Macrophages Plays a Key Role in the Suppression of Anti-Tumor Immunity,” Cell Reports 42 (2023): 113224.

[144] C. Hung, X. Xu, L. Li, et al., “Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy,” Human Gene Therapy 29 (2018): 614–625.

[145] J. Li, P. Chen, and W. Ma, “The Next Frontier in Immunotherapy: Potential and Challenges of CAR-Macrophages,” Experimental Hematology & Oncology 13 (2024): 76.

[146] T. Yan, L. Zhu, and J. Chen, “Current Advances and Challenges in CAR T-Cell Therapy for Solid Tumors: Tumor-Associated Antigens and the Tumor Microenvironment,” Experimental Hematology & Oncology 12 (2023): 14.

[147] C. Sloas, S. Gill, and M. Klichinsky, “Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors,” Frontiers in Immunology 12 (2021): 783305.

[148] Y. Zhang, J. Yang, T. Zhang, and H. Gu, “Emerging Advances in Nanobiomaterials-Assisted Chimeric Antigen Receptor (CAR)-Macrophages for Tumor Immunotherapy,” Frontiers in Bioengineering and Biotechnology 11 (2023): 1211687.

[149] F. Feng, J. Shen, Q. Qi, Y. Zhang, and S. Ni, “Empowering Brain Tumor Management: Chimeric Antigen Receptor Macrophage Therapy,” Theranostics 14 (2024): 5725–5742.

[150] A. Morva, A. B. Arroyo, L. Andreeva, A. Tapia-Abellán, and G. Luengo-Gil, “Unleashing the Power of CAR-M Therapy in Solid Tumors: A Comprehensive Review,” Frontiers in Immunology 16 (2025): 1615760.

[151] Y. Liang, Q. Xu, and Q. Gao, “Advancing CAR-Based Immunotherapies in Solid Tumors: CAR-Macrophages and Neutrophils,” Frontiers in Immunology 14 (2023): 1291619.

[152] S. Yang, Y. Wang, J. Jia, et al., “Advances in Engineered Macrophages: A New Frontier in Cancer Immunotherapy,” Cell Death & Disease 15 (2024): 238.

[153] N. Li, S. Geng, Z. Dong, et al., “A New Era of Cancer Immunotherapy: Combining Revolutionary Technologies for Enhanced CAR-M Therapy,” Molecular Cancer 23 (2024): 117.

[154] K. M. Maalej, M. Merhi, V. P. Inchakalody, et al., “CAR-Cell Therapy in the Era of Solid Tumor Treatment: Current Challenges and Emerging Therapeutic Advances,” Molecular Cancer 22 (2023): 20.

[155] J. Fu, D. Wang, D. Mei, et al., “Macrophage Mediated Biomimetic Delivery System for the Treatment of Lung Metastasis of Breast Cancer,” Journal of Controlled Release 204 (2015): 11–19.

[156] Y. Huang, Z. Guan, X. Dai, et al., “Engineered Macrophages as Near-Infrared Light Activated Drug Vectors for Chemo-Photodynamic Therapy of Primary and Bone Metastatic Breast Cancer,” Nature Communications 12 (2021): 4310.

[157] H. Sakai, S. Kokura, T. Ishikawa, et al., “Effects of Anticancer Agents on Cell Viability, Proliferative Activity and Cytokine Production of Peripheral Blood Mononuclear Cells,” Journal of Clinical Biochemistry and Nutrition 52 (2013): 64–71.

[158] C. Fan, Y. Lee, Y. Ho, C. Wang, S. Kang, and C. Yeh, “Macrophages as Drug Delivery Carriers for Acoustic Phase-Change Droplets,” Ultrasound in Medicine & Biology 44 (2018): 1468–1481.

[159] S. Li, S. Feng, L. Ding, et al., “Nanomedicine Engulfed by Macrophages for Targeted Tumor Therapy,” International Journal of Nanomedicine 11 (2016): 4107–4124.

[160] J. Choi, H. Kim, E. J. Ju, et al., “Use of Macrophages to Deliver Therapeutic and Imaging Contrast Agents to Tumors,” Biomaterials 33 (2012): 4195–4203.

[161] Y. Tao, M. Ning, and H. Dou, “A Novel Therapeutic System for Malignant Glioma: Nanoformulation, Pharmacokinetic, and Anticancer Properties of Cell-Nano-Drug Delivery,” Nanomedicine 9 (2013): 222–232.

[162] Y. Ikehara, T. Niwa, L. Biao, et al., “A Carbohydrate Recognition-Based Drug Delivery and Controlled Release System Using Intraperitoneal Macrophages as a Cellular Vehicle,” Cancer Research 66 (2006): 8740–8748.

[163] L. Pang, Y. Zhu, J. Qin, W. Zhao, and J. Wang, “Primary M1 Macrophages as Multifunctional Carrier Combined With PLGA Nanoparticle Delivering Anticancer Drug for Efficient Glioma Therapy,” Drug Delivery 25 (2018): 1922–1931.

[164] N. Doshi, A. J. Swiston, J. B. Gilbert, et al., “Cell-Based Drug Delivery Devices Using Phagocytosis-Resistant Backpacks,” Advanced Materials 23 (2011): H105–109.

[165] Y. Chang, H. Guo, J. Li, et al., “Adjusting the Balance Between Effective Loading and Vector Migration of Macrophage Vehicles to Deliver Nanoparticles,” PLoS ONE 8 (2013): e76024.

[166] C. A. Holden, Q. Yuan, W. A. Yeudall, D. A. Lebman, and H. Yang, “Surface Engineering of Macrophages With Nanoparticles to Generate a Cell-nanoparticle Hybrid Vehicle for Hypoxia-Targeted Drug Delivery,” International Journal of Nanomedicine 5 (2010): 25–36.

[167] J. Li, Y. Wu, J. Wang, et al., “Macrophage Membrane-Coated Nano-Gemcitabine Promotes Lymphocyte Infiltration and Synergizes AntiPD-L1 to Restore the Tumoricidal Function,” ACS Nano 17 (2023): 322–336.

[168] M. Xuan, J. Shao, L. Dai, Q. He, and J. Li, “Macrophage Cell Membrane Camouflaged Mesoporous Silica Nanocapsules for In Vivo Cancer Therapy,” Advanced Healthcare Materials 4 (2015): 1645–1652.

[169] M. S. Kim, M. J. Haney, Y. Zhao, et al., “Development of Exosome-Encapsulated Paclitaxel to Overcome MDR in Cancer Cells,” Nanomedicine 12 (2016): 655–664.

[170] D. H. Kim, H. Kim, Y. J. Choi, et al., “Exosomal PD-L1 Promotes Tumor Growth Through Immune Escape in Non-Small Cell Lung Cancer,” Experimental & Molecular Medicine 51 (2019): 1–13.

[171] W. Hong, K. Du, Q. Zhang, Z. Ren, and X. Gao, “Tanreqing Suppresses the Proliferation and Migration of Non-Small Cell Lung Cancer Cells by Mediating the Inactivation of the HIF1α Signaling Pathway via Exosomal Circ-WDR78,” Journal of Biomolecular Structure & Dynamics 43 (2025): 2491–2502.

[172] M. Poggio, T. Hu, C. Pai, et al., “Suppression of Exosomal PD-L1 Induces Systemic Anti-Tumor Immunity and Memory,” Cell 177 (2019): 414–427. e413.

[173] K. Wu, K. Lin, X. Li, et al., “Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment,” Frontiers in Immunology 11 (2020): 1731.

[174] H. Jeong, I. Hwang, S. H. Kang, H. C. Shin, and S. Y. Kwon, “Tumor-Associated Macrophages as Potential Prognostic Biomarkers of Invasive Breast Cancer,” Journal of Breast Cancer 22 (2019): 38–51.

[175] E. Strack, P. A. Rolfe, A. F. Fink, et al., “Identification of Tumor-Associated Macrophage Subsets That Are Associated With Breast Cancer Prognosis,” Clinical and Translational Medicine 10 (2020): e239.

[176] Y. Huang, M. Wang, Y. Sun, et al., “Macrophage Spatial Heterogeneity in Gastric Cancer Defined by Multiplex Immunohistochemistry,” Nature Communications 10 (2019): 3928.

[177] P. Neuperger, K. Szalontai, N. Gémes, et al., “Single-Cell Mass Cytometric Analysis of Peripheral Immunity and Multiplex Plasma Marker Profiling of Non-Small Cell Lung Cancer Patients Receiving PD-1 Targeting Immune Checkpoint Inhibitors in Comparison With Platinum-Based Chemotherapy,” Frontiers in Immunology 14 (2023): 1243233.

[178] C. Xiang, M. Zhang, Z. Shang, et al., “Single-Cell Profiling Reveals the Trajectory of FOLR2-Expressing Tumor-Associated Macrophages to Regulatory T Cells in the Progression of Lung Adenocarcinoma,” Cell Death & Disease 14 (2023): 493.

[179] Y. Gu, W. Zhu, Z. Zhang, H. Shu, H. Huang, and X. Sun, “Integrated Single-Cell Analysis Dissects Regulatory Mechanisms Underlying Tumor-Associated Macrophage Plasticity in Hepatocellular Carcinoma,” Genes (Basel) 16 (2025): 817.

[180] W. Chen, S. Zeng, J. Zhong, et al., “Mapping Immune Cell Dynamics and Macrophage Plasticity in Breast Cancer Tumor Microenvironment Through Single-Cell Analysis,” Discover Oncology 16 (2025): 625.

[181] Y. Xin, Q. Ma, Q. Deng, T. Wang, D. Wang, and G. Wang, “Analysis of Single-Cell and Spatial Transcriptomics in TNBC Cell-Cell Interactions,” Frontiers in Immunology 16 (2025): 1521388.

[182] M. Rakina, I. Larionova, and J. Kzhyshkowska, “Macrophage Diversity in Human Cancers: New Insight Provided by Single-Cell Resolution and Spatial Context,” Heliyon 10 (2024): e28332.

[183] M. Motevasseli, M. Darvishi, A. Khoshnevisan, et al., “Distinct Tumor-TAM Interactions in IDH-Stratified Glioma Microenvironments Unveiled by Single-Cell and Spatial Transcriptomics,” Acta Neuropathologica Communications 12 (2024): 133.

[184] W. Liu, A. Puri, D. Fu, et al., “Dissecting the Tumor Microenvironment in Response to Immune Checkpoint Inhibitors via Single-Cell and Spatial Transcriptomics,” Clinical & Experimental Metastasis 41 (2024): 313–332.

[185] X. Song, Y. Zhu, W. Geng, et al., “Spatial and Single-Cell Transcriptomics Reveal Cellular Heterogeneity and a Novel Cancer-Promoting Treg Cell Subset in Human Clear-Cell Renal Cell Carcinoma,” Journal for ImmunoTherapy of Cancer 13 (2025): e010183.

[186] F. Verona, S. Di Bella, R. Schirano, et al., “Cancer Stem Cells and Tumor-Associated Macrophages as Mates in Tumor Progression: Mechanisms of Crosstalk and Advanced Bioinformatic Tools to Dissect Their Phenotypes and Interaction,” Frontiers in Immunology 16 (2025): 1529847.

[187] X. Zheng, A. Weigert, S. Reu, et al., “Spatial Density and Distribution of Tumor-Associated Macrophages Predict Survival in Non-Small Cell Lung Carcinoma,” Cancer Research 80 (2020): 4414–4425.

[188] L. Fu, W. Du, M. Cai, J. Yao, Y. Zhao, and X. Mou, “The Roles of Tumor-Associated Macrophages in Tumor Angiogenesis and Metastasis,” Cellular Immunology 353 (2020): 104119.

[189] H. Wang, T. Tian, and J. Zhang, “Tumor-Associated Macrophages (TAMs) in Colorectal Cancer (CRC): From Mechanism to Therapy and Prognosis,” International Journal of Molecular Sciences 22 (2021): 8470.

[190] R. N. Ramos, C. Rodriguez, M. Hubert, et al., “CD163(+) Tumor-Associated Macrophage Accumulation in Breast Cancer Patients Reflects Both Local Differentiation Signals and Systemic Skewing of Monocytes,” Clinical & Translational Immunology 9 (2020): e1108.

[191] C. Wang, Y. Lin, H. Zhu, et al., “The Prognostic and Clinical Value of Tumor-Associated Macrophages in Patients with Breast Cancer: A Systematic Review and Meta-Analysis,” Frontiers in Oncology 12 (2022): 905846.

[192] L. Li, L. Han, F. Sun, et al., “NF-κB RelA Renders Tumor-Associated Macrophages Resistant to and Capable of Directly Suppressing CD8(+) T Cells for Tumor Promotion,” Oncoimmunology 7 (2018): e1435250.

[193] Y. Mano, S. Aishima, N. Fujita, et al., “Tumor-Associated Macrophage Promotes Tumor Progression via STAT3 Signaling in Hepatocellular Carcinoma,” Pathobiology 80 (2013): 146–154.

[194] L. Yan, F. Xu, and C. L. Dai, “Relationship Between Epithelial-to-Mesenchymal Transition and the Inflammatory Microenvironment of Hepatocellular Carcinoma,” Journal of Experimental & Clinical Cancer Research 37 (2018): 203.

[195] D. Jiang, R. Xiao, J. Bai, et al., “FOLR2(+) Macrophages in Cancer: Allies or Enemies,” Cell Communication and Signaling 23 (2025): 261.

[196] S. Takeo, K. Yasumoto, A. Nagashima, H. Nakahashi, K. Sugimachi, and K. Nomoto, “Role of Tumor-Associated Macrophages in Lung Cancer,” Cancer Research 46 (1986): 3179–3182.

[197] Z. Ge and S. Ding, “The Crosstalk Between Tumor-Associated Macrophages (TAMs) and Tumor Cells and the Corresponding Targeted Therapy,” Frontiers in Oncology 10 (2020): 590941.

[198] S. Chen, A. F. Saeed, Q. Liu, et al., “Macrophages in Immunoregulation and Therapeutics,” Signal Transduction and Targeted Therapy 8 (2023): 207.

[199] N. Yanagawa, S. Shikanai, M. Sugai, et al., “Prognostic and Predictive Value of CD163 Expression and the CD163/CD68 Expression Ratio for Response to Adjuvant Chemotherapy in Patients With Surgically Resected Lung Squamous Cell Carcinoma,” Thorac Cancer 14 (2023): 1911–1920.

[200] Y. Wang, N. Zhu, J. Liu, et al., “Role of Tumor Microenvironment in Ovarian Cancer Metastasis and Clinical Advancements,” Journal of Translational Medicine 23 (2025): 539.

[201] M. Yin, X. Li, S. Tan, et al., “Tumor-Associated Macrophages Drive Spheroid Formation During Early Transcoelomic Metastasis of Ovarian Cancer,” Journal of Clinical Investigation 126 (2016): 4157–4173.

[202] X. Ma, Y. Gao, Y. Chen, et al., “M2-Type Macrophages Induce Tregs Generation by Activating the TGF-β/Smad Signalling Pathway to Promote Colorectal Cancer Development,” OncoTargets and Therapy 14 (2021): 5391–5402.

[203] C. Li, X. Dong, and B. Li, “Tumor Microenvironment in Oral Squamous Cell Carcinoma,” Frontiers in Immunology 15 (2024): 1485174.

[204] R. Liu, J. Li, L. Liu, W. Wang, and J. Jia, “Tumor-Associated Macrophages (TAMs): Constructing an Immunosuppressive Microenvironment Bridge for Pancreatic Ductal Adenocarcinoma (PDAC),” Cancer Pathogenesis and Therapy 3 (2025): 183–196.

[205] S. Yang, Q. Liu, and Q. Liao, “Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Origin, Polarization, Function, and Reprogramming,” Frontiers in Cell and Developmental Biology 8 (2020): 607209.

[206] S. Yu, S. Wang, X. Wang, and X. Xu, “The Axis of Tumor-Associated Macrophages, Extracellular Matrix Proteins, and Cancer-Associated Fibroblasts in Oncogenesis,” Cancer Cell International 24 (2024): 335.

[207] L. Cassetta and T. Kitamura, “Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors,” Frontiers in Cell and Developmental Biology 6 (2018): 38.

[208] F. Liu, X. Li, Y. Zhang, et al., “Targeting Tumor-Associated Macrophages to Overcome Immune Checkpoint Inhibitor Resistance in Hepatocellular Carcinoma,” Journal of Experimental & Clinical Cancer Research 44 (2025): 227.

[209] C. Ceci, M. G. Atzori, P. M. Lacal, and G. Graziani, “Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse Into Novel Therapeutic Approaches for Metastatic Melanoma,” Cancers (Basel) 12 (2020): 3401.

[210] W. Zhao, H. Wang, X. Zhang, et al., “Effects of IFN-γ on the Immunological Microenvironment and TAM Polarity in Stage IA Non-Small Cell Lung Cancer and Its Mechanisms,” BMC Pulmonary Medicine 24 (2024): 46.

[211] S. Wang, Y. Yang, P. Ma, et al., “Landscape and Perspectives of Macrophage -Targeted Cancer Therapy in Clinical Trials,” Molecular Therapy Oncolytics 24 (2022): 799–813.

[212] T. Chen, W. Hung, S. Chiang, et al., “Dual Inhibition of TGFβ Signaling and CSF1/CSF1R Reprograms Tumor-Infiltrating Macrophages and Improves Response to Chemotherapy via Suppressing PD-L1,” Cancer Letters 543 (2022): 215795.

[213] M. Y. Li, W. Ye, and K. W. Luo, “Immunotherapies Targeting Tumor-Associated Macrophages (TAMs) in Cancer,” Pharmaceutics 16 (2024): 865.

[214] A. F. Saeed, “Tumor-Associated Macrophages: Polarization, Immunoregulation, and Immunotherapy,” Cells 14 (2025): 741.

[215] J. Xu, L. Ding, J. Mei, et al., “Dual Roles and Therapeutic Targeting of Tumor-Associated Macrophages in Tumor Microenvironments,” Signal Transduction and Targeted Therapy 10 (2025): 268.

[216] S. S. Mojsilovic, S. Mojsilovic, V. H. Villar, and J. F. Santibanez, “The Metabolic Features of Tumor-Associated Macrophages: Opportunities for Immunotherapy?,” Analytical Cellular Pathology (Amsterdam) 2021 (2021): 5523055.

[217] L. Xiao, Q. Wang, and H. Peng, “Tumor-Associated Macrophages: New Insights on Their Metabolic Regulation and Their Influence in Cancer Immunotherapy,” Frontiers in Immunology 14 (2023): 1157291.

[218] M. Peng, Y. Zhu, Y. Hu, J. Wen, and W. Huang, “Advances in the Regulation of Macrophage Polarization by the Tumor Microenvironment,” Discover Oncology 16 (2025): 1487.

[219] S. Qin, B. Xie, Q. Wang, et al., “New Insights Into Immune Cells in Cancer Immunotherapy: From Epigenetic Modification, Metabolic Modulation to Cell Communication,” MedComm 5 (2024): e551.

[220] G. Wei, B. Li, M. Huang, et al., “Polarization of Tumor Cells and Tumor-Associated Macrophages: Molecular Mechanisms and Therapeutic Targets,” MedComm 6 (2025): e70372.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.